Background Sleep deprivation and fatigue are common subjective complaints among astronauts. We conducted the first large-scale evaluation of objectively-estimated sleep of astronauts on both short- and long-duration spaceflight missions. Methods Allnon-Russian crewmembers assigned to space shuttle flights with inflight experiments from July 2001 until July 2011 or ISS Expeditions from 2006 –2011 were eligible to participate. We objectively assessed, via wrist actigraphy and daily logs, sleep-wake timing of 64 astronauts on 80 Space Shuttle missions, encompassing 26 Space Transportation System flights (1,063 inflight days), and 21 astronauts on the International Space Station (ISS) (3,248 inflight days) and, for each astronaut, during two Earth-based data-collection intervals prior to and one following spaceflight (4,013 ground-based days). Findings Astronauts attempted and obtained significantly less actigraphically-estimated sleep per night on space shuttle missions (7·35 ± 0·47 and 5·96 ± 0·56 hours, respectively), in the 11-days before spaceflight (7·35 ± 0·51 and 6·04 ± 0·72 hours, respectively) and even three months before spaceflight (7·40 ± 0·59 and 6·29 ± 0·67 hours, respectively) than they did upon their return to Earth (8·01 ± 0·78 and 6·74 ± 0·91 hours, respectively) (p < 0·0001 for each) Astronauts on ISS missions also obtained significantly less sleep three months prior (6.41 ± 0.65), in the 11 days prior (5.86 ± 0.94) and during spaceflight (6.09 ± 0.67 hours), as compared to the first week post-mission (6.95 ± 1.04 hours; p < 0·0001). Seventy-eight percent (61/78) of shuttle mission-crewmembers reported taking a dose of sleep-promoting medications on 52% of nights (500/963) and 2 doses on 17% of nights during flight (87/500); 75% of ISS crewmembers (12/16) reported using sleep-promoting medications. Interpretation Sleep deficiency in astronauts was prevalent not only during space shuttle and ISS missions, but also throughout a 3-month pre-flight training interval. Despite chronic sleep curtailment, sleeping pill use was pervasive during spaceflight. As chronic sleep loss produces performance decrements, these findings highlight the need for development of effective counter measures to promote sleep. Funding The study was supported by NASA cooperative agreement NCC 9–119. Drs. Czeisler and Barger received support from the NSBRI (HFP01601).
Sleep deficiency and the use of sleep-promoting medication are prevalent during spaceflight. Operations frequently dictate work during the biological night and sleep during the biological day, which contribute to circadian misalignment. We investigated whether circadian misalignment was associated with adverse sleep outcomes before (preflight) and during spaceflight missions aboard the International Space Station (ISS). Actigraphy and photometry data for 21 astronauts were collected over 3,248 days of long-duration spaceflight on the ISS and 11 days prior to launch (n=231 days). Sleep logs, collected one out of every 3 weeks in flight and daily on Earth, were used to determine medication use and subjective ratings of sleep quality. Actigraphy and photometry data were processed using Circadian Performance Simulation Software to calculate the estimated endogenous circadian temperature minimum. Sleep episodes were classified as aligned or misaligned relative to the estimated endogenous circadian temperature minimum. Mixed-effects regression models accounting for repeated measures were computed by data collection interval (preflight, flight) and circadian alignment status. The estimated endogenous circadian temperature minimum occurred outside sleep episodes on 13% of sleep episodes during preflight and on 19% of sleep episodes during spaceflight. The mean sleep duration in low-Earth orbit on the ISS was 6.4±1.2 h during aligned and 5.4±1.4 h (P<0.01) during misaligned sleep episodes. During aligned sleep episodes, astronauts rated their sleep quality as significantly better than during misaligned sleep episodes (66.8±17.7 vs. 60.2±21.0, P<0.01). Sleep-promoting medication use was significantly higher during misaligned (24%) compared with aligned (11%) sleep episodes (P<0.01). Use of any medication was significantly higher on days when sleep episodes were misaligned (63%) compared with when sleep episodes were aligned (49%; P<0.01). Circadian misalignment is associated with sleep deficiency and increased medication use during spaceflight. These findings suggest that there is an immediate need to deploy and assess effective countermeasures to minimize circadian misalignment and consequent adverse sleep outcomes both before and during spaceflight.
The basic goal of this research is to determine the best combination of light wavelengths for use as a lighting countermeasure for circadian and sleep disruption during space exploration, as well as for individuals living on Earth. Action spectra employing monochromatic light and selected monochromatic wavelength comparisons have shown that short‐wavelength visible light in the blue‐appearing portion of the spectrum is most potent for neuroendocrine, circadian, and neurobehavioral regulation. The studies presented here tested the hypothesis that broad spectrum, polychromatic fluorescent light enriched in the short‐wavelength portion of the visible spectrum is more potent for pineal melatonin suppression in healthy men and women. A total of 24 subjects were tested across three separate experiments. Each experiment used a within‐subjects study design that tested eight volunteers to establish the full‐range fluence–response relationship between corneal light irradiance and nocturnal plasma melatonin suppression. Each experiment tested one of the three types of fluorescent lamps that differed in their relative emission of light in the short‐wavelength end of the visible spectrum between 400 and 500 nm. A hazard analysis, based on national and international eye safety criteria, determined that all light exposures used in this study were safe. Each fluence–response curve demonstrated that increasing corneal irradiances of light evoked progressively increasing suppression of nocturnal melatonin. Comparison of these fluence–response curves supports the hypothesis that polychromatic fluorescent light is more potent for melatonin regulation when enriched in the short‐wavelength spectrum.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.